caa a22 4500 477072089 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/BF02627955 doi (NATIONALLICENCE)springer-10.1007/BF02627955 An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension [Elektronische Daten] [Richard Byyny, Debora Merrill, Thomas Bradstreet, Charles Sweet] Summary: The antihypertensive activity and safety of losartan, a specific and selective antogonist of angiotensin II (subtype 1) receptors, was evaluated in 100 inpatients with mild to moderate essential hypertension. After a 2-week, single-blind, out patient placebo lead-in period, the last 2 days of which included inpatient monitoring of baseline blood pressure, the patients were assigned randomly to receive once-daily doses of either placebo; 50, 100, or 150 mg losartan; or 10 mg enalapril. Patients were treated double blind for 5 days, followed by a day for the study of drug withdrawal. Beginning with the first dose, the three doses of losartan and enalapril significantly decreased peak and trough systolic and diastolic blood pressures compared with placebo (p<-0.05). The area under the blood pressure curve was analyzed as an assessment of total blood pressure change throughout the day. On day 1, total blood pressure reduction with losartan (50-150 mg) was slightly less than with enalapril. By day 5 of double-blind treatment, the reduction in blood pressure in these groups was similar, suggesting that losartan has a slower onset of action than enalapril. No rebound hypertension was observed after study-drug discontinuation. Losartan was well tolerated in this trial, with an adverse event profile similar to placebo and enalapril. Kluwer Academic Publishers, 1996 Iosartan nationallicence enalapril nationallicence mild to moderate essential hypertension nationallicence inpatient trial nationallicence Byyny Richard University of Colorado Health Sciences Center, Denver, CO, USA aut Merrill Debora Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut Bradstreet Thomas Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut Sweet Charles Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 313-319 0920-3206 10:3<313 1996 10 10557 https://doi.org/10.1007/BF02627955 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02627955 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Byyny Richard University of Colorado Health Sciences Center, Denver, CO, USA aut NATIONALLICENCE 700 1- Merrill Debora Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut NATIONALLICENCE 700 1- Bradstreet Thomas Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut NATIONALLICENCE 700 1- Sweet Charles Clinical Cardiovascular Research, Merck Research Laboratories, PA, West Point aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 313-319 0920-3206 10:3<313 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer